Delays in getting Leqembi and other potential Alzheimer’s drugs to patients early can be costly to the healthcare system, too, as Alzheimer’s patients require special, more expensive care as the disease progresses. A study in June by University of Chicago professor Tomas Philipson who has served as a top healthcare economist and advisor at the FDA and CMS said delays in access to Alzheimer’s treatments could increase costs for patients and the health system by up to $546 billion.
Read the full article here.